Microsoft word - lmx4 eloquest msds 2012.docx

Material Safety Data Sheet – L.M.X.4® This Material Safety Data sheet is not intended for consumers and does not address consumer use of the product. For information regarding consumer applications of this product, refer to the product labeling. PRODUCT & COMPANY IDENTIFICATION
Product Name:
Marketed by:
Manufactured by: Ferndale Laboratories, Inc.
Emergency Telephone: For emergency involving spill, leak, fire exposure or accident, call
Product Technical and
Medical Information:

(OSHA-regulated, present at ≥ 1%)
Chemical Name
Exposure Limits in Air
(by weight)
Listed Carcinogens: The following components, present at concentrations of ≥0.1% are listed as carcinogens or potential
carcinogens by either the National Toxicology Program (NTP), the International Agency for Research on Cancer (IARC),
OSHA or ACGIH: None.
National Fire Protection Association (NFPA)
Emergency Overview - Toxic
Adverse Effects:
Adverse effects may include numbness, burning, stinging or swelling of skin, drowsiness or excitement, nervousness, dizziness, blurred vision, tremors, convulsions, unconsciousness, and possible cardiac arrest. When taken orally, lidocaine may cause nausea, vomiting, or abdominal discomfort. Possible allergic reaction to material if inhaled, ingested, or in contact with skin. Overdose Effects:
Symptoms of overdose include low blood pressure; blurred or double vision; nausea or vomiting; ringing in ears; tremors or twitching; difficult breathing; increased sweating; change in heart rate with possible cardiac arrest; pale skin; vision or hearing disturbances; feeling hot, cold, or numb; confusion; convulsions; dizziness; Material Safety Data Sheet – L.M.X.4® drowsiness; trembling; anxiety or nervousness; headache; weakness; coma; and death. Appearance:
Potential Health Effects
May be harmful if inhaled. May cause irritation. Eye Contact:
Skin Contact:
Repeated or prolonged contact may cause irritation. Ingestion:
May be harmful if swallowed. May cause abdominal cramps and diarrhea. FIRST AID MEASURES
Inhalation: Remove to fresh air immediately. If not breathing, give artificial respiration. Get
Immediately flush eyes with plenty of water for at least 15 minutes. If irritation and/or stinging persist get medical attention immediately. Continue to rinse. Flush skin thoroughly with water. Get medical attention if symptoms persist or occur after washing. Ingestion:
Avoid ingestion. Wash out mouth with water if conscious. Do NOT induce vomiting. Obtain medical attention immediately. Components of this product are rapidly absorbed from the gastrointestinal tract. FIRE FIGHTING
Flammable Properties:
Not flammable. However, during fire, gases hazardous to health may be formed. Flash Point:
Extinguishing Media:
CO2, alcohol-resistant foam, water spray or dry chemical. Do not use Special Fire Fighting
Self-contained breathing apparatus and full protective clothing should Procedures:
Personal Protection:
Use personal protection recommended in Section 8 of the MSDS. Spill Cleanup Methods:
Cover with inert, absorbent material and remove to disposal container. Spill area may be slippery. Flush with plenty of water. Dispose of absorbed material in accordance with local and state regulations. HANDLING AND STORAGE
Store at controlled room temperature between 59-86oF (15-30oC) Material Safety Data Sheet – L.M.X.4® EXPOSURE CONTROLS/PERSONAL PROTECTION
Engineering Controls:
Respiratory Protection:
Not applicable; aerosol formation is extremely unlikely. Eye Protection:
None required during normal administration or use of L.M.X.4®. Avoid contact with eyes. When handling large quantities, use approved eye protection to safeguard against potential eye contact. Protective Clothing:
Prolonged skin contact may require protective gloves. Hygienic Work Practices: Wash hands thoroughly after handling. If working with large quantities
of the cream (such as spill clean-up), use chemical resistant gloves and appropriate eye protection. No eating, drinking or smoking in area. PHYSICAL AND CHEMICAL PROPERTIES
Nonvolatile Residue:
Stable under normal ambient and anticipated storage and handling conditions of temperature and pressure. Components are hygroscopic. Conditions to avoid:
Avoid exposure to moisture and high temperatures. Materials to avoid:
Avoid contact with strong oxidizing agents, mineral acids, strong acids, caustics, aliphatic amines, and isocyanates. Hazardous Decomposition
Emits toxic fumes under fire conditions. Combustion can yield carbon Products:
dioxide, carbon monoxide, and other oxides. Hazardous Polymerization: Will not occur.
 Skin Rabbit LD50: > 10000 mg/kg  Oral Rat: 20 g/kg Irritancy Data:
Benzyl Alcohol:
 Rabbit/Skin: skin irritation – 24 h Material Safety Data Sheet – L.M.X.4® Other Carcinogenicity Data: Metabolites of lidocaine have been shown to be carcinogenic in
laboratory animals.
Reproductive Effects: Studies in animals have not shown that lidocaine causes adverse events on the
fetus. It has been used a local anesthetic during delivery. The Center for the Evaluation of Risks to
Human Reproduction concluded that propylene glycol is not a reproductive or developmental toxicant
in animals, and that human developmental or reproductive risks are of negligible concern.
Mutagenicity: Lidocaine hydrochloride was not shown to be mutagenic in the Salmonella/mammalian
microsome test nor clastogenic in chromosome aberration assay with human lymphocytes and mouse
micronucleus test. Propylene glycol was found to cause DNA inhibition and was positive in cytogenic
studies in mice and hamster fibroblasts. It has been negative in the Ames Salmonella assay.
Low toxicity to aquatic organisms. Low potential for bioaccumulation. Prevent spilled material from
entering sewers, storm drains, other unauthorized drainage systems, and natural waterways.
Dispose of waste in accordance with all local, state, and federal laws and regulations (contact local or
state environmental agency for specific rules). Do not dispose of via sinks, drains, or into immediate
This product is not a hazardous material for DOT, IATA, IMO or TDG shipment.
This product contains no components subject to reporting or notification requirements. SARA Title III:
Notice: The preceding information is based on available data compiled by the manufacturer from its
own studies and the work of others and is believed to be correct. However, no warranty is expressed
or implied as to the accuracy, completeness or adequacy of this information, the results to be obtained
from the use thereof or the hazards connected with the use of the material. Since the information
contained herein may be applied under conditions beyond our control and with which we may be
unfamiliar, Ferndale Laboratories, Inc. does not assume any responsibility for the results of its use.
The information is furnished upon the condition that the persons receiving it shall make their own
determination as to the suitability of the product for their particular use.



Division of Emergency Medical Services 3 Capitol Hill, Providence, RI 02908-5097 Tel (401)222-2401 SUBJECT: Pre-hospital Administration of Amiodarone To ensure consistency in patient care, the Division of EMS has prepared the fol owing guidelines for administration of amiodarone in the pre-hospital environment. This information is intended to supplement the current Rhode

Tratto da

Il caso Avandia. Da una parte milioni di pazienti che hanno assunto questo farmacoe 83.000 persone che, solo negli USA, sono andate incontro ad eventicardiovascolari, talvolta letali. Dal ’altra parte del a barricata molte persone(manager, azionisti, consulenti, etc) che dal a malattia e dal a morte di questepersone si sono criminalmente arricchite, deliberatamente occultando eminimizzando dat

Copyright ©2018 Sedative Dosing Pdf